Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 701 - 725 of 1445 in total

K-00546

Experimental

MK-0731

MK-0731 is a kinesin spindle protein inhibitor and antineoplastic agent.
Experimental

MK-0777

MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.
Investigational

MK-0752

Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).
Investigational

MK-0533

MK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).
Investigational

CYP-001

CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational

MK-0773

MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational

IN01

The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria . These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence . Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing antibodies . Of note,...
Investigational

STG-001

STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt Disease).
Investigational

ENB-003

ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.
Investigational

MK-0482

MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational

GEN-001

Investigational

AMT-080

AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
Investigational

ALX-009

Investigational

BSG-005

Investigational

BBT-059

BBT-059 is a long-acting interleukin-11 analog.
Investigational

ABX-002

Investigational

TLY-012

TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated TRAIL).
Investigational

TRK-001

TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.
Investigational

PAS-004

PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational

BVX-001

BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational

APL-030

APL-030 is a orally-active small molecule inhibitor of GCN2.
Investigational

TAK-071

TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson Disease).
Investigational

PF-03758309

PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational

Phthalocyanine

Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Investigational
Matched Iupac: … 2,11,20,29,37,38,39,40-octaazanonacyclo[28.6.1.1³,¹⁰.1¹²,¹⁹.1²¹,²⁸.0⁴,⁹.0¹³,¹⁸.0²²,²⁷.0³¹,³⁶]tetraconta …
Displaying drugs 701 - 725 of 1445 in total